Replies to post #212940 on Bioelectronics Corp (BIEL)

[JustGoDeep]

Money Lenders Hostile Take Over Failed

Money Lenders Lost.

Biel!!

Monster!!

[ninaaa]

They reduced their debt which is key.
This instills confidence, buying power and a new listing.

BIEL knows about this and the decision lies with the company.
BIEL also knows the cutting advantage we have compared to their competitor and I have no doubt they will use this advantage to their advantage.

GO BIEL !!

[gimmee greenbacks]

Looks like your plan needs a little tweaking..

Kelly has ruled out implementing a Reverse Split for the next two years.

Most would consider that an extremely positive development.



BIEL

[4toSchool]

Not only uplisting first, but ENDV has a much higher product price point per pemf unit. IDK, but I assume that their products are already on insurance formulary lists. That is the key to big revenue.

[Biotech_Tradez]

What are you going on about? I have worked at two different investment firms with healthcare focus and none would touch ENDV nor BIEL with a ten foot pole.

These companies are in the middle of their Bar Mitzvah moment where they have to show that they are a real company. They have to show massive growth and a path toward profitability. Neither are even close. And getting FDA Clearance is no big deal, generating sales is the big deal. FDA Clearance means they are allowed to market it that doesn't mean there is a demand from payers. OTC sales are difficult as other pain management companies have found out.

[srinsocal]

Hmmmm, The OTC Markets says that ENDV has been on the OTCQB Exchange for 4 and a half years.

I would agree that OTCQB opens up a larger investor pool than the Pink Sheets. However ENDV has only owned the patents to Sofpulse for 2 years so they did not upgrade Exchanges "to leave BIEL behind".

"OTCQB Member Since 06/2015"

https://www.otcmarkets.com/stock/ENDV/overview

IMO BIEL has nothing to fear from ENDV. They dug a deep financial hole when they purchased the Sofpulse Patents from Rio Grande for $4.5 Million in 12/2017. Since then they have had constant heavy dilution to pay for the purchase, seeing their SP plummet from .0649 to .0013 .

ENDV has had 2 Reverse Splits, in 5/2014 a 1 for 100 RS and in 12/2019 a 1 for 1000 RS.

In June of 2019 the ENDV's CEO Allan Collier announced a Sofpulse National Rollout which would involve 300 Sales Reps, make ENDV cash flow positive by the end of the year, and generate $300 million in sales in 2020.

This was a total BS Pump for his dilution machine. ENDV did $54k in sales according to their last financial statement, Q3 2019.

ENDV has done a couple of Pump PRs, giving out samples to NFL Teams, expanding into Plastic Surgery with no names mentioned, but never any dollar values given.

BIEL is Light Years ahead of ENDV, with FDA OTC Clearance, ENDV is prescription only, product cost of $29 for ActiPatch, $89 for RecoveryRx, vs $250 for Sofpulse.

https://www.globenewswire.com/news-release/2019/06/13/1868389/0/en/Endonovo-Therapeutics-Announces-National-Rollout-of-SofPulse-Post-Operative-Opioid-Alternative-into-Hospitals.html